A Prospective, Multicenter, Open-label, Single-arm Phase II Clinical Study Evaluating the Efficacy and Safety of Spatially Fractionated Radiotherapy Combined With the PraG Strategy for the Treatment of Soft Tissue Sarcoma

NCT07342322 | Not Yet Recruiting Phase 2

• 1 other identifier: 2025-K0608
• Study Type: interventional
• Target: 25
• Locations: 1 country
• Sites: 1

Brief Summary

The primary objective of this clinical trial is to evaluate the efficacy and safety of spatially fractionated radiotherapy combined with the PraG strategy in the treatment of soft tissue sarcoma (STS). The main questions it aims to answer are:

1. 1.Can spatially fractionated radiotherapy combined with the PraG strategy improve the clinical prognosis of patients?
2. 2.What medical adverse events and clinical problems will participants encounter during the treatment with spatially fractionated radiotherapy combined with the PraG strategy? Researchers will administer a combined therapeutic regimen consisting of spatially fractionated radiotherapy, Toripalimab, recombinant human granulocyte-macrophage colony-stimulating factor injection, and Thymalfasin injection to enrolled patients, so as to observe the efficacy and safety of this therapeutic strategy for soft tissue sarcoma.
3. 3.The treatment will be divided into two major phases: the radiotherapy phase and the immunotherapy phase, with concomitant immunomodulatory supportive therapy administered throughout the entire treatment course.
4. 4.The total duration of treatment will last for 1 year starting from the first dose of medication, with regular clinical evaluations conducted according to the individual disease characteristics of each patient.
5. 5.Participants will receive daily oral administration of ABC or placebo for a consecutive 4 months.
6. 6.Routine follow-up examinations will be performed at an interval of 8/12 weeks.
7. 7.Clinical symptoms, imaging indicators, biochemical parameters and survival status of all participants will be systematically recorded and documented throughout the study period.

Conditions

Soft Tissue Sarcoma (STS)

Outcome Measures

Primary Outcomes (1)

• Objective Response Rate

  week 4

Secondary Outcomes (1)

• Disease Control Rate

  week 4

Study Arms (1)

SFRT + PraG

EXPERIMENTAL

Drug: Spatially Fractionated Radiation Therapy Combined with Toripalimab and Human Granulocyte-Macrophage Colony-Stimulating Factor for Injection

Interventions

Spatially Fractionated Radiation Therapy Combined with Toripalimab and Human Granulocyte-Macrophage Colony-Stimulating Factor for Injection DRUG

1. Spatially Fractionated Radiation Therapy: 1. High-dose area: 500-800 cGy × 3 fractions 2. Fraction interval: 1 session of radiotherapy per day, with 3 sessions per cycle 3. High-dose area coverage: 40-60% of the irradiated field area 2. Toripalimab: 1. Dose: 3 mg/kg 2. Frequency: Every 2-3 weeks 3. Administration timing: Within one week after the completion of radiotherapy 3. Human Granulocyte-Macrophage Colony-Stimulating Factor for Injection: 1. Dose: 100-200 µg 2. Frequency: Once daily <!-- --> 1. Administration timing: Starting on the day of radiotherapy, to be used continuously for one week

SFRT + PraG

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age: 18-75 years old, both genders are eligible.
• Pathological Diagnosis: Histologically confirmed soft tissue sarcoma, including but not limited to:
• Undifferentiated pleomorphic sarcoma
• Liposarcoma
• Leiomyosarcoma
• Synovial sarcoma
• Fibrosarcoma
• Other high-grade soft tissue sarcomas
• Disease Stage:
• Locally advanced, unresectable soft tissue sarcoma, or
• Recurrent or metastatic soft tissue sarcoma
• Prior Therapy:
• Prior surgery, radiotherapy, or chemotherapy is allowed.
• At least 4 weeks since the last anti-tumor treatment.
• Prior treatment-related toxicities have resolved to ≤Grade 1 (except alopecia).

You may not qualify if:

• Special Types of Sarcoma:
• Gastrointestinal Stromal Tumor (GIST)
• Osteosarcoma
• Ewing's Sarcoma
• Prior Treatment History:
• Previous radiotherapy to the same site with a cumulative dose that may exceed the normal tissue tolerance dose
• Major surgery within 4 weeks
• Concurrent Diseases:
• Active autoimmune diseases
• Diseases requiring systemic immunosuppressive therapy
• Severe cardiovascular diseases (myocardial infarction, unstable angina, heart failure, etc.)
• Severe pulmonary diseases (interstitial pneumonia, pulmonary fibrosis, etc.)
• Active infections requiring systemic anti-infective therapy
• Central Nervous System Metastasis: Symptomatic brain or spinal metastasis.
• Pregnancy and Lactation: Women who are pregnant or breastfeeding.

Sponsors & Collaborators

• First Affiliated Hospital of Guangxi Medical University: lead

Study Sites (1)

the First Affiliated Hospital of Guangxi Medical University

Nanning, Guangxi, 530021, China

Location

MeSH Terms

Conditions

Sarcoma

Interventions

toripalimab; Injections

Condition Hierarchy (Ancestors)

Neoplasms, Connective and Soft Tissue; Neoplasms by Histologic Type; Neoplasms

Intervention Hierarchy (Ancestors)

Drug Administration Routes; Drug Therapy; Therapeutics

Central Study Contacts

Jun Lv

CONTACT

86 + 13481095127; 87800197@qq.com

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 8, 2026
• First Posted: January 15, 2026
• Study Start: February 1, 2026
• Primary Completion: February 1, 2026
• Study Completion (Estimated): January 31, 2029
• Last Updated: January 15, 2026

Record last verified: 2026-01

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)